Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study

Journal of the American College of Cardiology

Volumn 40, Issue 5, 2002, Pages 970-975

  Wong, Maylene ^a   Staszewsky, Lidia ^b   Latini, Roberto ^b   Barlera, Simona ^b   Volpi, Alberto ^b   Chiang, Yann Tong ^c   Benza, Raymond L ^d   Gottlieb, Sidney O ^e   Kleemann, Thomas D ^f   Rosconi, Franco ^g   Vandervoort, Pieter M ^h   Cohn, Jay N ⁱ  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Midatlantic Cardiovascular Associates   (United States)

^f KLINIKUM LUDWIGSHAFEN   (Germany)

^g RHO HOSPITAL   (Italy)

^h DEPARTMENT OF CARDIOLOGY   (Belgium)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VALSARTAN;

ADULT; AGE; AGED; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DISEASE CLASSIFICATION; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SEX RATIO; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0037019554     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02063-6     Document Type: Article

References (22)

1. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
3. The effect of carvedilol on morbidity, and mortality in patients with chronic heart failure
4. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
5. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure
6. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure
7. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease
8. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure
9. Cardiac remodeling - Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling
10. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs Cooperative Studies V-HeFT I and II
11. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD Echocardiographic Substudy
12. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease
13. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
14. Quality assessment and quality control of echocardiographic performance in a large multi-center international study: Valsartan in Heart Failure Trial (Val-HeFT)
15. Baseline demographics of the Valsartan Heart Failure Trial
16. Time course of improvement in left ventricular function, mass and geometry, in patients with congestive heart failure treated with beta-adrenergic blockade
17. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart
18. 1 receptor subtype
19. Pathological hypertrophy and the cardiac interstitium: Fibrosis and the renin-angiotensin-aldosterone system
20. Tissue renin-angiotensin systems in the pathophysiology of heart failure
21. Effect of vasodilator therapy on mortality in chronic congestive heart failure
22. Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change